Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial - Nakagawa, K; Garon, E B; Seto, T; RELAY Study Investigators (Lancet Oncol, 2019)